

## Enantioselective Synthesis of (+)- and (-)-Muricatacin through $S_E2'$ Addition of Nonracemic $\gamma$ -Silyloxy Allylic Stannanes to Aldehydes

James A. Marshall\* and Gregory S. Welmaker


Department of Chemistry and Biochemistry, University of South Carolina,  
Columbia, South Carolina 29208

Received March 15, 1994<sup>o</sup>

The acetogenins (*R,R*)-(+)- and (*S,S*)-(-)-muricatacin were synthesized through the highly stereoselective addition of  $\gamma$ -silyloxy allylic stannanes (*S*)-**6** and (*R*)-**6** to (*E*)-ethyl 3-formylpropenoate (**12**) in the presence of  $\text{BF}_3\cdot\text{OEt}_2$ . The resulting adducts (*R,R*)-**13** and (*S,S*)-**13** afforded the aforementioned acetogenins upon catalytic hydrogenation and subsequent deprotection-lactonization with aqueous HF. Interestingly, additions of stannanes **6** (racemic) to the saturated aldehydes  $\text{RCH}_2\text{CH}_2\text{CHO}$  (**8**,  $\text{R} = \text{CO}_2\text{Et}$ ,  $\text{R} = \text{CN}$ ,  $\text{R} = \text{Cl}$ ) in the presence of  $\text{BF}_3\cdot\text{OEt}_2$  afforded *ca.* 70:30 mixtures of *syn* and *anti* adducts **9a-c**. In contrast, the *n*-alkyl aldehyde **8** ( $\text{R} = n\text{-C}_4\text{H}_9$ ) underwent highly selective *syn* addition (97:3) with the crotyl analogue **7** of stannane **6**.

The recent isolation and structure elucidation of muricatacin (**III**) from the seeds of the tropical fruit *Annona muricata* L.<sup>1</sup> has stimulated a great deal of attention,<sup>2</sup> no doubt stemming from the wide range of biological properties attributed to muricatacin and its more complex congeners.<sup>3</sup> Interestingly, both enantiomers of muricatacin are found in nature. The isolated material is a mixture of the two, with the (-)-(*R,R*) enantiomer predominant (ee of *ca.* 25% based on the optical rotation of synthetic material).<sup>2,4</sup>

Our synthetic plan, outlined in eq 1, entailed addition of a nonracemic  $\gamma$ -alkoxy allylic stannane **II** to a succinaldehyde derivative **I** followed by hydrogenation and lactonization. Related  $S_E2'$  additions are known to be stereospecific with respect to the stannane reagent and highly *syn* selective overall.<sup>5</sup> It was expected that the (*S*) reagent (*S*)-**II** would give rise to (*R,R*)-muricatacin and vice versa.



Our recent findings that TBS-protected stannanes such as **II** ( $\text{R}^1 = \text{TBS}$ ) show improved *syn* selectivity in Lewis

acid-promoted additions to aldehydes prompted our choice of (*S*)-**6** and (*R*)-**6** as the stannane reagents.<sup>5b</sup> These were synthesized by addition of  $\text{Bu}_3\text{SnLi}$  to tridecenal **1**,<sup>6</sup> followed by *in situ* oxidation of the intermediate alkoxide with diisopropyl azodicarboxylate.<sup>7</sup> The crude acyl stannane **2** was reduced with (*R*)-BINAL-H or (*S*)-BINAL-H to afford the (*S*)- $\alpha$ -hydroxy stannane (*S*)-**3** or the enantiomer (*R*)-**3**, respectively.<sup>8</sup> Treatment with TBSCl and imidazole led to the  $\alpha$ -OTBS allylic stannanes (*S*)-**5** and (*R*)-**5**. <sup>1</sup>H NMR analysis of the *O*-methyl mandelate derivatives (*S*)-**4** and (*R*)-**4** of the hydroxy stannane precursors indicated an enantiomeric excess of >95% for each stannane reagent.<sup>9</sup>

Upon stirring with  $\text{BF}_3\cdot\text{OEt}_2$  in  $\text{CH}_2\text{Cl}_2$  at  $-78^\circ\text{C}$ , each of the  $\alpha$ -silyloxy stannanes (*S*)-**5** and (*R*)-**5** smoothly isomerized to the  $\gamma$ -isomers (*S*)-**6** (88% yield) and (*R*)-**6** (95% yield). Alternatively, the  $\gamma$ -isomer (*R*)-**6** could be obtained directly from the crude  $\alpha$ -hydroxy stannane (*R*)-**3** with TBSOTf and *i*-Pr<sub>2</sub>NEt at  $0^\circ\text{C}$ .<sup>5b</sup> Both procedures were equally efficient based on starting enal **1**.

The requisite succinic aldehyde ester **8** ( $\text{R} = \text{CO}_2\text{Et}$ ) was prepared through ozonolysis of ethyl 4-pentenoate<sup>10</sup> and subsequent reductive workup with  $\text{Me}_2\text{S}$ . Addition

(3) Rupprecht, J. K.; Hui, Y. H.; McLaughlin, J. L. *J. Nat. Prod.* **1990**, *53*, 237.

(4) A portion of this work has appeared in preliminary form: Marshall, J. A.; Welmaker, G. S. *Synlett* **1992**, 537.

(5) (a) Cf. Marshall, J. A.; Welmaker, G. S.; Gung, B. W. *J. Am. Chem. Soc.* **1991**, *113*, 647. (b) Marshall, J. A.; Welmaker, G. S. *J. Org. Chem.* **1992**, *57*, 7158.

(6) 2-Tridecenal (**1**) is available from Pflatz and Bauer. Our sample was prepared by Wittig-homologation of undecanal (Aldrich Chemical) with (carbomethoxymethylene)triphenylphosphorane followed by reduction and Swern oxidation: Omura, K.; Swern, D. *Tetrahedron* **1978**, *34*, 1651.

(7) We have previously employed 1,1'-(azodicarbonyl)dipiperidine (ADD) for this *in situ* oxidation.<sup>5</sup> Cf. Narasaka, K.; Morikawa, A.; Saigo, K.; Mukaiyama, T. *Bull. Chem. Soc. Jpn.* **1977**, *50*, 2773. We are grateful to Prof. Cava (Alabama) for suggesting azodicarboxylic esters as less expensive alternatives.

(8) Noyori, R.; Tomino, I.; Tanimoto, Y.; Nishizawa, M. *J. Am. Chem. Soc.* **1984**, *106*, 6709.


(9) The ee of the hydroxy stannane was calculated from the <sup>1</sup>H NMR spectra of the (*S*)- and (*R*)-*O*-methyl mandelates. Cf. Trost, B. M.; Belletire, J. L.; Godleski, S.; McDougal, P. G.; Balkovec, J. M.; Baldwin, J. J.; Christy, M. E.; Ponticello, G. S.; Varga, S. L.; Springer, J. P. *J. Org. Chem.* **1986**, *51*, 2370.

(10) Aldrich Chemical, Milwaukee, WI. Cf. (a) Peak, D. A.; Robinson, R.; Walker, J. J. *J. Chem. Soc.* **1936**, 733. (b) Battersby, A. R.; Hunt, E.; McDonald, E.; Moron, J. *J. Chem. Soc., Perkin Trans. 1* **1973**, 2917.

<sup>o</sup> Abstract published in *Advance ACS Abstracts*, June 15, 1994.

(1) Rieser, M. J.; Kozlowski, J. F.; Wood, K. V.; McLaughlin, J. L. *Tetrahedron Lett.* **1981**, *32*, 1137.

(2) (a) Figadère, B.; Harmange, J.-C.; Laurens, A.; Cavé, A. *Tetrahedron Lett.* **1991**, *32*, 7539. (b) Scholz, G.; Tochtermann, W. *Tetrahedron Lett.* **1991**, *32*, 5535. (c) Wang, Z.-M.; Lian, X.-L.; Sharpless, K. B.; Sinha, S. C.; Sinha-Bagchi, A.; Keimman, E. *Tetrahedron Lett.* **1992**, *33*, 6407.




of stannane (*S*)-6 to this aldehyde in the presence of  $\text{BF}_3 \cdot \text{OEt}_2$  at  $-78^\circ\text{C}$  afforded the adduct **9a** in 84% yield as a 70:30 mixture of *syn* and *anti* diastereomers (Table 1, entry 1). This result was rather surprising, as we had previously obtained the adducts of the corresponding crotyl stannane **7** and heptanal as a 97:3 *syn:anti* mixture (entry 6). When the crotyl reagent was employed with the foregoing aldehyde ester, the *syn:anti* ratio increased to 88:12 (entry 2). Thus, it would appear that the diastereoselectivity of the addition is somewhat dependent on the nature of  $R^1$  in the stannane reagent and even more dependent on the aldehyde  $\beta$ -substituent  $R^2$ .<sup>11</sup>

Suspecting that complexation between the  $\text{BF}_3$  Lewis acid and the ester carbonyl may be responsible for the diminished stereoselectivity of the addition,<sup>12</sup> we examined the cyano aldehyde **8** ( $R^2 = \text{CN}$ ).<sup>13</sup> Unfortunately, this addition fared no better. The *syn* and *anti* adducts **9b** were formed in a ratio nearly equal to that from the corresponding ester aldehyde (entry 3). Again, the crotyl stannane **7** showed a somewhat higher *syn:anti* selectivity (entry 4). Hoping to further decrease the presumed interaction of  $\text{BF}_3$  with the aldehyde  $\beta$ -substituent, we next examined the  $\beta$ -chloro aldehyde **8** ( $R^2 = \text{Cl}$ ).<sup>14</sup> However, no significant improvement in the *syn:anti* ratio of adducts **9c** was observed. These experiments suggest a through-space or dipole-dipole interaction between the  $\beta$ -substituent  $R^2$  and the  $\text{BF}_3$  complex of aldehydes **8** may cause decreased diastereoselectivity.<sup>12</sup>

We have previously found that conjugated aldehydes give high ratios of *syn:anti* adducts with allyl stan-


Table 1.  $\text{BF}_3$ -Promoted Addition of  $\gamma$ -Silyloxy Allylic Stannanes to  $\beta$ -Substituted Aldehydes



entry	$R^1$	$R^2$	adduct	yield, %	<i>syn:anti</i> <sup>a</sup>
1	$n\text{-C}_{10}\text{H}_{21}$	$\text{CO}_2\text{Et}$	9a <sup>b</sup>	84	70:30
2	$\text{CH}_3$	$\text{CO}_2\text{Et}$	10a <sup>c</sup>	82	88:12
3	$n\text{-C}_{10}\text{H}_{21}$	$\text{CN}$	9b <sup>d</sup>	80	68:32
4	$\text{CH}_3$	$\text{CN}$	10b <sup>c</sup>	75	82:18
5	$n\text{-C}_{10}\text{H}_{21}$	$\text{Cl}$	9c <sup>d</sup>	76	72:28
6	$\text{CH}_3$	$n\text{-C}_4\text{H}_9$	10d <sup>e</sup>	86	97:3 <sup>e</sup>

<sup>a</sup> Ratios secured through integration of the  $^1\text{H}$  NMR spectra of crude product mixtures. <sup>b</sup> The (*S*)-stannane (*S*)-6 was employed. <sup>c</sup> The racemic stannane (*R,S*)-7 was employed. <sup>d</sup> The racemic stannane (*R,S*)-6 was employed. <sup>e</sup> Data from ref 5b.

anes.<sup>5,15</sup> We therefore turned our attention to the enal ester **12** as a possible aldehyde substrate. The (*E*)-double bond of **12** would also prohibit any through-space interaction of the ester carbonyl with the intermediate  $\text{BF}_3$  complex of the aldehyde.



(11) We have found that the isopropyl analogue of silyloxy stannane **6** ( $R = i\text{-Pr}$ ) fails to react with certain  $\alpha$ -benzyloxy aldehydes in the presence of  $\text{MgBr}_2$  under conditions where the related MOM or BOM derivatives afford adducts in high yield: Marshall, J. A.; Luke, G. P. *J. Org. Chem.* **1993**, *58*, 6229.

(12) An effect of this type was previously observed by Yamamoto *et al.* in the  $\text{BF}_3$ -promoted addition of tributyl crotylstannane to a  $\gamma$ -carbomethoxy aldehyde: Yamamoto, Y.; Yatagai, H.; Ishihara, Y.; Maeda, N.; Maruyama, R. *Tetrahedron* **1984**, *40*, 2239.

(13) Cyano aldehyde **8** ( $R^2 = \text{CN}$ ) was prepared by ozonolysis of 4-pentenitrile followed by reductive workup with  $\text{Me}_2\text{S}$ : Sumitomo, H.; Kobayashi, K. *J. Polym. Sci., Part A-1* **1972**, *10*, 2479. It was used without purification.

(14) Chloro aldehyde **8** ( $R^2 = \text{Cl}$ ) was prepared by Swern oxidation<sup>6</sup> of 3-chloro-1-propanol: MacLeod, A. J.; Rossiter, J. J. *J. Chem. Soc., Perkin Trans. 1* **1983**, 717. It was used without purification.

(15) For a recent review: Marshall, J. A. *Chemtracts-Org. Chem.* **1992**, 75.

Enal **12** was prepared by selective ozonolysis of ethyl sorbate (**11**) and reductive workup.<sup>16</sup> Addition of stannane (*R*)-6 in the presence of  $\text{BF}_3 \cdot \text{OEt}_2$  at  $-78^\circ\text{C}$  afforded the adduct (*S,S*)-13 in 79% yield as a ca. 95:5 mixture of *syn* and *anti* adducts. As expected, the addition of stannane (*S*)-6 to aldehyde **12** was equally selective. We were also able to carry out these additions with the  $\alpha$ -silyloxy stannanes by pretreatment with  $\text{BF}_3 \cdot \text{OEt}_2$  prior to aldehyde addition. Yields for both methods were comparable.

(16) Veysoglu, T.; Mitscher, L. A.; Swayze, J. K. *Synthesis* **1980**, 807.

The assigned stereochemistry of adducts (*S,S*)- and (*R,R*)-**13** is based on ample literature precedent.<sup>5,15</sup> The ee of these products was estimated to be ca. 95% or better from <sup>1</sup>H NMR analysis of the *O*-methyl mandelates **14**. Each of the allylic alcohol adducts was subjected to catalytic hydrogenation, affording the tetrahydro products (*S,S*)- and (*R,R*)-**15**. Concomitant silyl ether cleavage and lactonization with aqueous HF gave rise to the enantiomeric muricatacins (+)-(*S,S*)-**16** and (-)-(*R,R*)-**16**. The optical rotations and melting points of these samples were in close agreement with reported values.<sup>2</sup>

The foregoing syntheses illustrate the use of nonracemic  $\gamma$ -silyloxy stannanes as chiral reagents for the preparation of selectively monoprotected 1,2-diols. The work also uncovers an unexpected and intriguing effect of aldehyde  $\beta$ -substituents which can lower the diastereoselectivity of the addition. We further note that stereoselectivity can also be diminished through introduction of a long-chain alkyl group at the  $\alpha$  position (**R**<sup>1</sup> in **6**; see Table 1). The origin of this effect has yet to be elucidated, but steric interactions with BF<sub>3</sub> in the aldehyde complex could be at least partially responsible.<sup>17</sup>

### Experimental Section<sup>18</sup>

**(S)-(E)-1-(Tri-*n*-butylstannyl)-2-tridecen-1-ol [(S)-**3**]**. To a stirred, cooled (0 °C) solution of 0.85 mL (6.1 mmol) of HN-(*i*-Pr)<sub>2</sub> in 20 mL of THF was added 2.4 mL (6.2 mmol) of 1.6 M *n*-BuLi in hexanes. The solution was stirred for 20 min at 0 °C and then 1.6 mL (5.9 mmol) of Bu<sub>3</sub>SnH was introduced. The resulting solution was stirred for 40 min at 0 °C and then cooled to -78 °C. To this solution was added 1.0 g (5.1 mmol) of 2-tridecenal<sup>6</sup> in 3 mL of THF. The reaction mixture was stirred for 15 min at -78 °C and then 1.5 mL (7.6 mmol) of diisopropyl azodicarboxylate was added. The suspension was warmed to 0 °C and stirred for 1 h. The reaction mixture was then quenched with saturated aqueous NH<sub>4</sub>Cl, the phases were separated, and the aqueous phase was extracted with ether. The combined organic layers were dried over MgSO<sub>4</sub>, concentrated under reduced pressure, dissolved in hexanes, filtered, and again concentrated under reduced pressure to give the crude acyl stannane **2**, which was used immediately.

A solution of 10 mL (10 mmol) of 1.0 M LiAlH<sub>4</sub> in THF was added to 10 mL of THF with stirring, and then 10 mL (10 mmol) of 1.0 M EtOH in THF was added over 30 min. The reaction mixture was stirred for 30 min at ambient temperature. To this mixture was added a solution of 2.9 g (10 mmol) of (*R*)-1,1'-bi-2-naphthol in 20 mL of THF over 1 h. The milky white reaction mixture was heated to reflux for 1 h, allowed to cool to ambient temperature, and then cooled to -78 °C. To this suspension was added the crude acyl stannane **2** in 10 mL of THF over 1 h. The reaction mixture was stirred for 8 h at -78 °C and then quenched with MeOH, followed by saturated aqueous NH<sub>4</sub>Cl. The phases were separated and the aqueous phase was treated with 3% HCl and extracted with ether. The organic layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product was diluted with 200 mL of hexanes and filtered, affording 2.8 g (97% recovery) of binaphthol, [ $\alpha$ ]<sub>D</sub> +34 (c 1.0, THF), mp 207 °C; reported [ $\alpha$ ]<sub>D</sub> +34 (c 1.0, THF), mp 208–210 °C.<sup>8</sup> [<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  7.98–7.87 (m), 7.39–7.12 (m), 5.02 (s).] The filtrate was concentrated under reduced pressure and the crude hydroxy stannane (*S*)-**3** was protected immediately. <sup>1</sup>H NMR analysis of the (*R*)-*O*-methyl mandelate derivative (*S*)-**4** showed a dr of 98:2.

**(S)-(E)-1-[(*tert*-Butyldimethylsilyloxy)-1-(tri-*n*-butylstannyl)-2-tridecene [(S)-**5**]**. To a stirred, cooled (0 °C) solution of crude hydroxy stannane (*S*)-**3** in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> was added 0.52 g (7.6 mmol) of imidazole, followed by 0.77 g

(5.1 mmol) of TBSCl. The thick reaction mixture was stirred for 30 min and then quenched with saturated aqueous NH<sub>4</sub>Cl and diluted with ether. The phases were separated and the aqueous phase was extracted with ether. The combined organic extracts were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Purification by flash chromatography through silica gel (elution with hexanes) afforded 1.4 g (45% from aldehyde **1**) of the  $\alpha$ -silyloxy stannane (*S*)-**5**: [ $\alpha$ ]<sub>D</sub> -53 (c 1.8, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  5.60 (dd, 1H, *J* = 15.1, 5.6 Hz), 5.32 (dt, 1H, *J* = 15.1, 6.9 Hz), 4.61 (d, 1H, *J* = 5.6 Hz), 1.98 (q, 2H, *J* = 6.9 Hz), 1.56–1.22 (m), 0.88 (s, 9H), 0.87 (t, 9H, *J* = 7.2 Hz), 0.86 (t, 3H, *J* = 7.3 Hz), 0.00 (6H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  134.5, 122.2, 69.4, 32.5, 31.9, 30.1, 29.7, 29.7, 29.6, 29.4, 29.2, 29.2, 29.2, 27.5, 25.9, 22.7, 18.2, 14.1, 13.7, 9.1, -4.5, -5.2. Anal. Calcd for C<sub>31</sub>H<sub>66</sub>OSiSn: C, 61.89; H, 11.06. Found: C, 61.75; H, 11.11.

**(Z)-(S)-1-[(*tert*-Butyldimethylsilyloxy)-3-(tri-*n*-butylstannyl)-2-tridecene [(S)-**6**]**. To a stirred, cooled (-78 °C) solution of 0.10 g (0.17 mmol) of  $\alpha$ -(silyloxy)stannane (*S*)-**5** in 2 mL of CH<sub>2</sub>Cl<sub>2</sub> was added 0.22  $\mu$ L (0.18 mmol) of BF<sub>3</sub>·OEt<sub>2</sub>. The solution was stirred for 40 min at -78 °C and then quenched with saturated aqueous NaHCO<sub>3</sub> and warmed to room temperature. The phases were separated and the aqueous phase was extracted with ether. The combined organic extracts were washed with brine, dried over anhydrous MgSO<sub>4</sub>, and concentrated under reduced pressure. Chromatography (elution with hexanes) of the crude product gave 88 mg (88%) of the  $\gamma$ -(silyloxy) stannane (*S*)-**6**: [ $\alpha$ ]<sub>D</sub> +115 (c 1.9, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  5.99 (d, 1H, *J* = 5.7 Hz), 4.40 (dd, 1H, *J* = 11.1, 5.7 Hz), 2.53 (m, 1H), 1.54–1.24 (m), 0.91 (s, 9H), 0.87 (t, 9H, *J* = 7.12 Hz), 0.83 (t, 3H, *J* = 7.3 Hz), 0.09 (6H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  134.1, 115.1, 33.3, 31.9, 30.5, 29.1, 29.1, 29.4, 29.1, 27.6, 27.2, 25.7, 25.7, 22.9, 22.7, 18.2, 14.1, 13.7, 8.9, -3.0, -5.2, -5.4. Anal. Calcd for C<sub>31</sub>H<sub>66</sub>OSiSn: C, 61.89; H, 11.06. Found: C, 61.81; H, 11.07.

**Ethyl (2*E*,6*E*)-(4*R*,5*R*)-5-[(*tert*-Butyldimethylsilyloxy)-4-hydroxy-2,6-heptadecadienoate [(*R,R*)-**13**]**. To a stirred, cooled (-78 °C) solution of 1.0 g (1.7 mmol) of  $\alpha$ -stannane (*S*)-**5** in 5 mL of CH<sub>2</sub>Cl<sub>2</sub> was added 0.31 mL (2.5 mmol) of BF<sub>3</sub>·OEt<sub>2</sub>. The resulting solution was stirred at -78 °C for 50 min and then a solution of 0.21 g (1.6 mmol) of (*E*)-3-formyl-2-propenoate (**12**)<sup>16</sup> in 2 mL of CH<sub>2</sub>Cl<sub>2</sub> was introduced. The reaction mixture was stirred at -78 °C for 25 min, quenched with saturated aqueous NaHCO<sub>3</sub>, diluted with ether, and allowed to warm to ambient temperature. The phases were separated and the aqueous phase was extracted with ether. The combined organic extracts were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by flash chromatography through silica gel (elution with 10% ethyl acetate-hexanes) to afford 0.56 g (77%) of the coupled product (*R,R*)-**13**, which was shown to be a >95:5 mixture of *syn:anti* isomers by <sup>1</sup>H NMR analysis. [ $\alpha$ ]<sub>D</sub> +14.1 (c 2.0, CHCl<sub>3</sub>); IR (neat) 3499, 1725, 1660 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  6.88 (dd, 1H, *J* = 15.7, 4.2 Hz), 6.09 (dd, 1H, *J* = 15.7, 1.9 Hz), 5.64 (dt, 1H, *J* = 15.4, 6.7 Hz), 5.38 (dd, 1H, *J* = 15.4, 7.5 Hz), 4.17 (q, 2H, *J* = 7.1 Hz), 4.06 (m, 1H), 3.92 (t, 1H, *J* = 6.7 Hz), 2.64 (d, 1H, *J* = 4.8 Hz), 2.01 (q, 2H, *J* = 6.7 Hz), 1.26 (t, 3H, *J* = 7.1 Hz), 1.24 (m, 16H), 0.86 (s, 9H), 0.85 (t, 3H, *J* = 7.0 Hz), 0.02 (6H) [distinguishable peaks for the *anti* isomer are visible at 3.19, 3.09, and 2.38]; <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  166.4, 146.5, 135.3, 128.8, 121.7, 76.9, 74.3, 60.3, 32.2, 31.9, 29.6, 29.6, 29.5, 29.3, 29.2, 29.0, 25.8, 22.7, 18.1, 14.2, 14.1, -3.9, -4.8. Anal. Calcd for C<sub>25</sub>H<sub>48</sub>O<sub>4</sub>Si: C, 68.13; H, 10.98. Found: C, 68.23; H, 11.01. The <sup>1</sup>H NMR spectrum of the *O*-methyl mandelate derivative (*R,R*)-**14** showed ca. 3% of a diastereomeric product according to integration of signals at 6.90 and 6.70 ppm arising from the C-3 vinylic proton.

**Ethyl (4*R*,5*R*)-5-[(*tert*-Butyldimethylsilyloxy)-4-hydroxyheptadecadienoate [(*R,R*)-**15**]**. A stirred suspension of 0.50 g (1.1 mmol) of dienoate (*R,R*)-**13** and 0.50 g of 5% Pd on activated carbon in 20 mL of EtOH was placed under a H<sub>2</sub> atmosphere. The reaction mixture was stirred for 2 h and then filtered through Celite. The filtrate was concentrated and the crude product was purified by flash chromatography through

(17) Cf. Denmark, S. E.; Henke, B. R.; Weber, E. *J. Am. Chem. Soc.* **1987**, *109*, 2512.

(18) For typical experimental protocols, see ref 5a.

silica gel (elution with 5% ethyl acetate-hexanes) to afford 0.43 g (86%) of the hydrogenated product (*R,R*)-**15**.  $[\alpha]_D -5.8$  (c 2.1, CHCl<sub>3</sub>); IR (neat) 3521, 1730 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  4.11 (q, 2 H, *J* = 7.1 Hz), 3.46 (m, 2 H), 2.45 (q, 2 H, *J* = 7.2 Hz), 2.17 (s, 1 H), 1.70 (q, 2 H, *J* = 7.4 Hz), 1.26–1.08 (m, 22 H), 1.23 (t, 3 H, *J* = 7.0 Hz), 0.88 (s, 9 H), 0.86 (t, 3 H, *J* = 6.9 Hz), 0.06 (6 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  177.8, 82.1, 74.6, 58.8, 33.1, 32.3, 30.1, 30.0, 30.0, 30.0, 29.9, 29.9, 29.7, 29.0, 26.2, 25.6, 24.0, 23.1, 18.8, 18.4, 14.5, -4.1, -4.1. Anal. Calcd for C<sub>25</sub>H<sub>52</sub>O<sub>4</sub>Si: C, 67.51; H, 11.78. Found: C, 67.66; H, 11.81.

(-)-Muricatacin [(*R,R*)-**16**]. To a stirred solution of 80 mg (0.17 mmol) of the hydroxy ester (*R,R*)-**15** in 6 mL of 1:1 THF:H<sub>2</sub>O was added 0.1 mL of 49% aqueous HF. The reaction mixture was stirred for 6 h at ambient temperature and then diluted with water and ether. The phases were separated and the aqueous phase was extracted with ether. The combined organic extracts were dried over anhydrous MgSO<sub>4</sub> and concentrated under reduced pressure. The product was purified by chromatography through silica gel (elution with 25% ethyl acetate-hexanes) to afford 43 mg (83%) of (-)-muricatacin.  $[\alpha]_D -23.3$  (c 1.8, CHCl<sub>3</sub>); mp 67–68 °C; IR (neat) 3575, 1768 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  4.39 (dt, 1 H, *J* = 7.4, 4.5 Hz), 3.54 (m, 1 H), 2.59, 2.49 (ABX, 2 H, *J*<sub>AB</sub> = 9.8 Hz,

*J*<sub>AX</sub> = 5.0 Hz, *J*<sub>BX</sub> = 0.9 Hz), 2.25–2.05 (m, 3 H), 1.55–1.19 (m), 0.85 (t, 3 H, *J* = 6.9 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  177.3, 83.0, 73.6, 33.0, 31.9, 29.7, 29.7, 29.6, 29.5, 29.4, 28.7, 25.5, 24.1, 22.7, 14.1. Anal. Calcd for C<sub>17</sub>H<sub>30</sub>O<sub>3</sub>: C, 71.79; H, 11.34. Found: C, 71.71; H, 11.33. Reported:  $[\alpha]_D -22.9$  (CHCl<sub>3</sub>); mp 72 °C;<sup>2b</sup>  $[\alpha]_D -23.1$  (c 2.36, CHCl<sub>3</sub>); mp 73–74 °C.<sup>2c</sup>

**Acknowledgment.** This work was supported by the National Institute of Allergy and Infectious Diseases, Grant R01 AI31422. G.S.W. is grateful to the ACS Division of Organic Chemistry and Glaxo, Inc. for a graduate fellowship (1991–1992). We thank Prof. M. P. Cava for suggesting the substitution of azodicarboxylic esters for ADD in the hydroxy stannane oxidations.

**Supplementary Material Available:** Experimental procedures for **9a–c**, **10a,b**, (*R*)-**3**, (*R*)-**5**, (*R*)-**6**, (*S,S*)-**13**, (*S,S*)-**15**, and (*S,S*)-**16**, and selected <sup>1</sup>H NMR spectra (23 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.